ATLASATLAS fair value
ATLAS has no fair value for this stock today.
abrdn Life Sciences Investors (HQL)
abrdn Life Sciences Investors stock price today, ATLAS forecast and fair value
Financial Services · Asset Management · NYSE
$18.00▲ +1.69%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
51%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on abrdn Life Sciences Investors in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On abrdn Life Sciences Investors
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives abrdn Life Sciences Investors a 51% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $17.17 and $18.96; in 9 out of 10, between $15.73 and $20.70. Estimated annual volatility is 31%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $538M
- P/E ratio
- 2.7
- Dividend yield
- 12.44%
- 52-week high
- $22.67
- 52-week low
- $15.66
- Revenue (12 months)
- $1.1M
- Revenue growth (YoY)
- -0.3%
- Earnings growth (YoY)
- -8.2%
- Return on equity
- 41.4%
- Free cash flow (12 months)
- $-4.4M
- Beta
- 0.72
What this means
ATLAS does not publish a fair value for HQL right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks HQL has traded between $15.66 and $22.67. Today it is 20.6% below that high and 15% above its low.
On the business: revenue fell 0.3% year over year; it trades at 2.7 times earnings.
Its beta is 0.72: it tends to move less than the market.
About the company
abrdn Life Sciences Investors is a closed-end fund that focuses on the life sciences sector.
Want to see everything about abrdn Life Sciences Investors?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does abrdn Life Sciences Investors do?
abrdn Life Sciences Investors is a closed-end fund that focuses on the life sciences sector.
What is the chance HQL goes up next month?
51%: close to a coin flip. In half of the simulated outcomes, HQL ends the month between $17.17 and $18.96.
How big is abrdn Life Sciences Investors and what is its P/E ratio?
abrdn Life Sciences Investors's market capitalization is $538M. Its price-to-earnings (P/E) ratio is 2.7: you pay $2.7 for each $1 of yearly earnings.
Does abrdn Life Sciences Investors pay a dividend?
Yes. HQL's current dividend yield is 12.44% at today's price ($18.00).
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer